Nessan Bermingham, PhD
Chief Executive Officer, President and Founder
"Decades of scientific research have laid the groundwork for the development of effective gene therapies and cellular delivery methods. In the last few years, some 1500 peer-reviewed publications have shown the potential of CRISPR/Cas9 technology for therapeutic use. We’re standing on the shoulders of scientific history to reach our goal of creating one-time curative treatments for many genetic diseases."
Tom Barnes, PhD
SVP, R&D eXtellia
"Working on CRISPR/Cas9 is like being at the edge of a vast new territory with endless applications for treating patients without any therapeutic options. I would never consider missing out on this once-in-a-lifetime opportunity to make something that could change the course of medicine."
John Leonard, MD
"Rarely does medicine enter a new era, but it’s happening now because of CRISPR/Cas9. It is one of the very few approaches in biotechnology today worthy of the word “transformative” and it’s nothing short of exhilarating to be a part of what will change so many lives."
David Morrissey, PhD
SVP, Platform & Delivery Technology
"We are building on the advancements made in the RNA therapeutics field and the resurgence of gene therapy. It’s such an exciting time for all of us at Intellia to have this unique opportunity to deliver on the vast potential of the CRISPR/Cas9 technology."
EVP, General Counsel & Operations
"CRISPR/Cas9 starts the foundation for an entirely new class of therapeutic products. Its true importance won’t be measured on a financial spreadsheet but on its impact on health care throughout the world."